KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Depreciation & Amortization (CF) (2016 - 2025)

Inovio Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $350198.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 16.48% year-over-year to $350198.0; the TTM value through Sep 2025 reached $1.5 million, down 19.04%, while the annual FY2024 figure was $1.8 million, 31.34% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $350198.0 at Inovio Pharmaceuticals, down from $356151.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $940578.0 in Q2 2022 and bottomed at $350198.0 in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $660697.0 (2021), against an average of $642071.8.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 40.67% in 2022 before it plummeted 39.99% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $905104.0 in 2021, then grew by 2.01% to $923328.0 in 2022, then crashed by 38.3% to $569687.0 in 2023, then fell by 18.43% to $464674.0 in 2024, then dropped by 24.64% to $350198.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Depreciation & Amortization (CF) are $350198.0 (Q3 2025), $356151.0 (Q2 2025), and $371367.0 (Q1 2025).